What Patheon does

Patheon is a global contract development and manufacturing organization (CDMO) and contract research organization (CRO) that operates as a wholly owned pharma services brand of Thermo Fisher Scientific (NYSE: TMO), following Thermo Fisher's take-private of the formerly NYSE-listed Patheon N.V. Founded in 1974 and headquartered in Raleigh, NC, Patheon provides pharmaceutical development and commercial manufacturing services to biotech and pharmaceutical sponsors across small molecules, biologics, cell and gene therapies, mRNA, viral vectors, and softgel/lipid-based dosage forms. The company employs 5,001–10,000 people across more than 60 manufacturing and service locations worldwide, with subsidiaries including BrammerBio (viral vectors/cell therapy), Henogen, Fisher Clinical Services, and Patheon Logistics/Priority Air Express supporting integrated clinical-to-commercial supply chains.

The company's core technical assets are a portfolio of proprietary development platforms — Accelerator™, Path to IND, OSDPredict™ (AI/ML-driven oral solid dose formulation), Quadrant 2™ (AI/ML-enabled solubility enhancement), Rapid Development Framework™, ATLAS (digital platform), and dbDNA — combined with large-scale physical assets such as 5,000L single-use bioreactor capacity, sterile fill-finish, and soft lozenge manufacturing capability. These platforms are intended to compress development timelines for sponsors and enable progression from preclinical through commercial supply within a single provider.

Patheon monetizes through fee-for-service contracts with biotech and pharma sponsors, structured around development milestones, scale-up campaigns, and commercial supply agreements across the drug lifecycle. Customers include both emerging biotechs (NewAmsterdam Pharma, NysnoBio) and established gene therapy developers (bluebird bio), spanning a broad sponsor size spectrum. The business is reported within Thermo Fisher's Pharma Services segment rather than as a stand-alone entity, and Patheon does not disclose its own revenue.

Name

Patheon

Legal name

Patheon N.V.

Website

https://patheon.com

Company type

Private

Founded year

1974

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Patheon is a global CDMO/CRO brand of Thermo Fisher Scientific providing pharmaceutical development, manufacturing, and supply chain services across small molecules, biologics, cell and gene therapies, and mRNA to biotech and pharma sponsors across 60+ global locations.

Ownership category

akta.pro rank

Product category

Pharmaceutical Contract Development and Manufacturing (CDMO)

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412), Scientific Research and Development Services (5417), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Drug Substance–Drug Product Integrated CDMO (HLAGABAG)

akta.pro secondary industries

Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK), Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB), Small-Molecule API & Intermediates CDMO (HLAGABAA), Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM), Cell Therapy CDMO (HLAGABAD), Biologics (mAbs/Recombinant Proteins) CDMO (HLAGABAC)

Keywords

• Pharmaceutical contract manufacturing
• Drug development services
• Clinical trial supply
• Biologics manufacturing services
• Advanced therapy CDMO

Headquarters

HQ city

Raleigh

HQ country

United States

HQ region

North America

Offices9 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain, Marketing or Sales

Revenue model

1. CDMO Professional Services: Contract development and manufacturing revenue from biotech and pharma sponsors for drug substance, drug product, and clinical/commercial manufacturing services across small molecule, large molecule, steriles, oral solid dose, softgels, advanced therapies, and viral vector modalities. Engagements are typically project-based with multi-year contracts and milestone-based delivery tied to development phases.
2. CRO Clinical Trial Services: Contract research revenue from clinical trial packaging, labeling, logistics, distribution, comparator sourcing, and ancillary supply management services offered across global trials with multi-year contract structures.
3. Thermo Fisher Financial Solutions Program: Financial solutions program helping biotech and pharma drug developers speed their journey from molecule to medicine to market, often tied to long-term service commitments and milestone-driven payments.

Pricing tiers

Go-to-market motion3 records

Distribution channels4 records

Marketing channels9 records

Core offering

Patheon operates as a global Contract Development and Manufacturing Organization (CDMO) providing end-to-end pharmaceutical services across small molecule (API, oral solid dose, softgels), biologics/large molecule, steriles, advanced therapies (viral vectors, mRNA, cell therapy), and clinical trial services (packaging, labeling, logistics). Its flagship Accelerator™ Drug Development framework integrates drug substance, drug product, clinical manufacturing, clinical research, and clinical supply chain management into a single 360° CDMO and CRO program, delivered from more than 60 global manufacturing and service locations for pharmaceutical and biotechnology sponsors.

Product overview

Patheon is the pharma services brand of Thermo Fisher Scientific and operates as a global Contract Development and Manufacturing Organization (CDMO) offering a portfolio of integrated drug development, manufacturing, and clinical supply services. Its flagship offering is the Accelerator™ Drug Development platform, which unifies 360° CDMO and CRO services across small molecule (API, Oral Solid Dose including OSDPredict™ AI-driven formulation and Soft Lozenge Technology), Steriles, Biologics / Large Molecule, Advanced Therapies (viral vectors, mRNA with pTRXi plasmid backbone, and cell therapy supported by the Rapid Development Framework™), Clinical Trial Services (packaging, labeling via ATLAS℠, ePly™, and ultra-low temperature labels, plus Omni Client Portal / Omni Client Warehouse), Commercial Services, Regulatory Services, and cross-cutting innovative solutions for Asset Advancement, Digital Enablement, Manufacturing, and Supply Chain. Rather than a single software product, Patheon's portfolio is a platform-plus-modules architecture where the Accelerator™ framework connects these specialized service lines and proprietary tools (such as OSDPredict™, Quadrant 2™, the patented Tamper Evident Carton, and the Distribution Automation System with cobots) under a coordinated CDMO/CRO operating model spanning more than 60 global sites.

Differentiator

Problem solved

Functional benefit

Brands

• Accelerator™ Drug Development: Thermo Fisher Scientific / Patheon branded 360° CDMO and CRO integrated drug development solution offering.
• OSDPredict™
• ATLAS℠
• ePly
• Quadrant 2™
• Soft Lozenge (patient-centric soft lozenge technology)
• Omni Client Portal / Omni Client Warehouse
• Rapid Development Framework™
• pTRXi plasmid DNA backbone

Products and services

• Accelerator™ Drug Development Integrated 360° CDMO and CRO program-management framework delivered under the Patheon pharma services brand that connects drug substance, drug product, clinical manufacturing, clinical research, and clinical supply chain management to compress timelines from molecule to medicine for pharmaceutical and biotechnology sponsors.
• Small Molecule Services (API, Oral Solid Dose, Softgels) End-to-end small molecule capabilities including API development and manufacturing, oral solid dose development and commercial manufacturing, and softgel lipid-based formulation technologies, with specialized high-potency OSD capabilities at the Bourgoin, France site, for pharmaceutical and biotech sponsors.
• Steriles Services Sterile product development and commercial manufacturing services with US- and EU-based PDS steriles facilities, including injectable formulation development in liquid and lyophilized formats, lyophilization services, and packaging for advanced parenteral therapies.
• Large Molecule / Biologics Services Biologics development and manufacturing offerings spanning cell line development using CHO K1 with transposase technology, process intensification, 5,000 L single-use bioreactor scale-up, viral vector and plasmid DNA services, and tech transfer support for biotech and pharma sponsors.
• Advanced Therapies Services (Viral Vectors, mRNA, Cell Therapy) End-to-end CDMO development and manufacturing services for advanced therapies including viral vectors (AAV, LV), mRNA drug substance and therapeutics manufacturing with pTRXi plasmid DNA backbone and doggybone DNA, and cell therapy manufacturing services, complemented by the Rapid Development Framework™ for cell and gene therapies.
• Clinical Trial Services Clinical packaging, labeling (including ultra-low temperature labels), logistics and distribution (cold chain, direct-to-patient), strategic comparator and ancillary sourcing, Enhanced Demand Planning, clinical ancillary supplies, and clinical manufacturing services, integrated with the global Thermo Fisher Clinical Services network for global clinical trials.
• Commercial Services Commercial-scale drug substance and drug product manufacturing services supporting late-stage and commercial supply, including tech transfer, scale-up, commercial packaging and labeling, and post-launch supply continuity.
• Regulatory Services Regulatory affairs and CMC support helping sponsors navigate FDA, EMA, and global health authority requirements across drug development, registration, and post-approval changes.
• Path to IND for Biologics Integrated program that accelerates biologics from DNA to drug product for First-in-Human (Phase I) clinical trials, leveraging CHO K1 cell line with transposase technology; positioned to deliver Phase I clinical trial material in as few as 9 months.
• Soft Lozenge Technology Proprietary patient-centric soft lozenge dosage form offering a soft and soothing mouthfeel with superior taste-masking, shell flavors, and a sugar-free option; designed for children, seniors, and patients with dysphagia.
• OSDPredict™ AI/ML Drug Formulation Platform Digital toolbox powered by AI and ML technology to help sponsors identify and address oral solid dose formulation challenges early in development, leveraging predictive modeling and decision-support workflows.
• Quadrant 2™ Bioavailability Enhancement Platform Platform leveraging AI/ML tools to identify solubility enhancement technologies for poorly soluble molecules, addressing bioavailability challenges in oral drug development.
• pTRXi Plasmid DNA Backbone Fully customizable plasmid DNA backbone designed to streamline and accelerate mRNA development workflows, complemented by cGMP plasmid DNA manufacturing services.
• Asset Advancement Comprehensive biopharma asset management capabilities supporting recently acquired or in-licensed assets across development, manufacturing, and commercialization stages, accessed via the Accelerator™ framework.
• Digital Enablement (Pharma 4.0) Digital solutions and best practices under Patheon's Pharma 4.0 strategy, including AI/ML-driven formulation tools, predictive modeling, the Omni Client Portal and Omni Client Warehouse platforms, and digital enablement of clinical trial supply chains.
• Manufacturing Solutions Manufacturing solutions and continuous quality improvement programs including flexible manufacturing models, process automation, real-time monitoring, and modular facility designs, leveraging Patheon's global network of more than 60 manufacturing locations.
• Supply Chain Solutions Proactive supply chain strategies for risk mitigation, contingency planning powered by data-driven insights and AI, and resilience programs including UK customs warehouse (Horsham) and India Special Economic Zone (Ahmedabad) operations.

Quantifiable outcome

• Reduced development timelines by 12 months and saved $1 million through integrated Accelerator™ Drug Development CDMO/CRO solutions
• +4 more outcomes

Named customers3 records

Segments5 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability7 records

Feature17 records

Partnerships

Nine partnerships are on record, tiered core, flagship and minor.

• Ethris GmbHcoreStrategic or Co-development Partner · 9 February 2026Patheon UK Limited manufactures vaccine materials for Ethris' proprietary SNIM®RNA and SNaP LNP® mRNA and lipid nanoparticle technology platforms as part of a strategic research collaboration with the German Center for Infection Research (DZIF) to develop next-generation mRNA-based vaccines targeting infectious diseases. The collaboration supports both preclinical and clinical development.
• German Center for Infection Research (DZIF)coreStrategic or Co-development Partner · 9 February 2026Under the strategic collaboration, DZIF gains access to Ethris' proprietary mRNA and lipid nanoparticle platforms, with vaccine materials manufactured by Patheon UK Limited and Evonik Operations GmbH, supporting both preclinical and clinical development of variant-ready mRNA vaccines addressing emerging pathogens, antimicrobial resistance, and underserved patient populations.
• Evonik Operations GmbHcoreStrategic or Co-development Partner · 9 February 2026Evonik Operations GmbH partners with Patheon UK Limited to manufacture vaccine materials under the strategic research collaboration between Ethris GmbH and DZIF to develop next-generation mRNA-based vaccines.
• Thermo Fisher ScientificflagshipStrategic or Co-development PartnerPatheon operates as Thermo Fisher Scientific's pharma services brand, delivering integrated CDMO and CRO solutions. Thermo Fisher Scientific is the parent entity, with Patheon N.V. and its subsidiaries referenced in the website terms of use. The partnership provides Patheon with global scale, digital enablement, and access to Thermo Fisher's broader portfolio including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, PPD, Gibco, and Ion Torrent brands.
• NysnoBiocoreStrategic or Co-development PartnerNysnoBio partnered with Patheon on a Quality by Design approach to viral vector development and manufacturing for an AAV-based gene therapy for Parkin-PD (Parkinson's disease). Featured in Patheon webinars and articles as a gene therapy development partner.
• bluebird biocoreStrategic or Co-development Partnerbluebird bio is cited as a partner who found viral vector development and manufacturing support through Patheon to deliver innovative gene therapies to patients across the continuum of gene therapy development stages.
• NewAmsterdam PharmacoreStrategic or Co-development PartnerNewAmsterdam Pharma partnered with Patheon as an integrated CDMO and CRO value-driving partner, executing 11 studies across 51 countries and delivering investigational medicinal products for over 12,000 patients across 835 clinical sites via a one-team approach to clinical supply management.
• Tufts Center for the Study of Drug Development (Tufts CSDD)minorImplementation/ SI/ Consulting PartnerPatheon cites Tufts CSDD benchmark data in whitepapers, webinars, and infographics to quantify the financial returns and risk-adjusted value of working with an integrated CDMO, CRO, and clinical supply partner, including the impact of CDMO–CRO integration on handoffs, silos, and development delays.
• Patheon UK LimitedflagshipOEM/ Whitelabel/ Licensing PartnerPatheon UK Limited is the Patheon subsidiary that manufactures mRNA-based vaccine materials under the Ethris/DZIF/Evonik collaboration, reflecting Patheon's manufacturing capacity in the United Kingdom for advanced therapy and vaccine production.

Scale indicators7 records

Recent moves6 records

Expansion highlights5 records

Market position

Competitive moat6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/165406
• Xx.com/patheon

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles13 records

Subsidiaries6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Patheon